AB&B BIO-TECH-B (02627) announced that the company's board of directors is pleased to announce that China's National Medical Products Administration (NMPA) has approved the group's new drug application for the quadrivalent influenza virus subunit vaccine targeting the population aged 6-35 months. As of the date of this announcement, this vaccine has become the first and only approved full-population, full-dose quadrivalent influenza virus subunit vaccine in China. This product represents a significant upgrade from traditional virus-split vaccines, offering advantages such as comprehensive protection, high purity of component antigens, and low risk of adverse reactions. The group is a China-headquartered vaccine company dedicated to the research, development, manufacturing, and commercialization of innovative vaccines and traditional vaccines using new technological approaches. The group closely tracks global disease incidence and vaccine development trends to determine its product pipeline, focusing on high-quality vaccines to replace traditional and imported vaccines in China while extending its competitive advantages to international markets. The group's products include, but are not limited to, quadrivalent influenza virus subunit vaccines, freeze-dried human rabies vaccines under development, and other vaccines in the research pipeline.